Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PharmaCyte Biotech ( (PMCB) ) has issued an update.
On August 17, 2025, PharmaCyte Biotech, Inc. announced a $7 million private placement financing with existing investors, involving the sale of 7,000 shares of newly designated Series C convertible preferred stock and warrants to purchase common stock. This financing, expected to close on August 19, 2025, is intended to strengthen PharmaCyte’s balance sheet and support its strategic initiatives, reflecting investor confidence in the company’s future prospects.
More about PharmaCyte Biotech
PharmaCyte Biotech, Inc. operates in the biotechnology industry, focusing on developing cellular therapies for cancer and diabetes. The company is known for its proprietary technology, Cell-in-a-Box®, which encapsulates genetically modified live cells for targeted treatment delivery.
Average Trading Volume: 21,639
Technical Sentiment Signal: Sell
Current Market Cap: $6.12M
For detailed information about PMCB stock, go to TipRanks’ Stock Analysis page.